Volume : VIII, Issue : III, March - 2018

Efficacy of Sofosbuvir and Daclatasvir in Hepatitis C virus Genotype 3, in treated and Naive patients. A Prospective study.

V. Venkata Ranga Reddy, G. Mohan Reddy, V. Lakshmi

Abstract :

 

More than 200 million people world wide have been infected with HCV­1.Evolution of the virus led to a geographic  distribution of genotypes, so that genotypes 1,2,and 3 are most common in North America and Europe,genotype 4 is the most common in the middle East, and genotype 6  is the most common in Southeast Asia2.Hepatitis C virus is responsible for parenterally transmitted,acute and chronic hepatitis.Chronic infection results in chronic active hepatitis,that may lead to cirrhosis,liver failure and hepato–cellular carcinoma. Chronic hepatitis develops in 50 to 90 % of persons with acute  HCV infection3.Approximately 3 percent of the world’s population is chronically infected with Hepatitis C virus and constitute a medical danger ,demanding anti–HCV vaccines and antiviral drugs.In India 12–18 million persons are infected with Hepatitis C virus and common genotype is 3.

Article:Download PDF Journal DOI : 10.15373/2249555X

Cite This Article:

V.Venkata Ranga Reddy, G.Mohan Reddy, V.Lakshmi, Efficacy of Sofosbuvir and Daclatasvir in Hepatitis C virus Genotype 3, in treated and Naive patients. A Prospective study., INDIAN JOURNAL OF APPLIED RESEARCH : Volume-8 | Issue-3 | March-2018


Article No. : 3


Number of Downloads : 153


References :